Latest news
BBIO: Attruby's strong Q2 growth and $1.7B cash position set the stage for three major launches - TradingViewTradingView · Mon, 10 Aug 2026 22:10:33 GMTOABI: Q2 2026 delivered strong revenue growth, clinical pipeline expansion, and new technology launches - TradingViewTradingView · Mon, 10 Aug 2026 11:44:42 GMTJBIO: Advancing three antibody therapies for autoimmune diseases with strong clinical and financial position - TradingViewTradingView · Mon, 10 Aug 2026 11:44:06 GMTEVMN: Advancing two novel anti-inflammatory therapies with strong clinical and financial momentum - TradingViewTradingView · Thu, 06 Aug 2026 21:19:26 GMTSABS: Strong clinical progress and financial position support SAB-142's advancement in T1D - TradingViewTradingView · Thu, 06 Aug 2026 13:52:46 GMTNTLA: Strong clinical and financial progress positions for potential first-in-class gene-editing launches - TradingViewTradingView · Thu, 06 Aug 2026 13:31:35 GMTCGON: Strong clinical progress and robust cash position support long-term operational runway - TradingViewTradingView · Thu, 06 Aug 2026 12:33:11 GMTEWTX: Asset sale and strong clinical progress drive over $2B cash and cardiovascular pipeline focus - TradingViewTradingView · Thu, 06 Aug 2026 12:10:29 GMT